SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jesspro who wrote (4331)6/30/2016 5:01:44 PM
From: Biomaven   of 4474
 
Yes, that article (which is new to me) does indeed suggest the possibility that pona doesn't fully penetrate the BBB. Could be you need a higher dose, or could be that you had resistance to pona caused by multiple drivers that emerged in the brain while the patient was on dasatinib or some earlier drug.

Ariad (if I recall correctly) claimed in some patent filings that, based on preclinical evidence, pona did penetrate the BBB.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News